Molecular Partners Ag (MOLN) FCF Margin (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly FCF Margin of 105.95% for Q1 2026, down 292.0% year-over-year from 55.18% in Q1 2025, and down 100.09% quarter-over-quarter from 114276.0% in Q4 2025.
Molecular Partners Ag (MOLN) FCF Margin (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported FCF Margin for 7 consecutive years, with 105.95% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 292.0% year-over-year to 105.95%; the TTM figure through Mar 2026 stood at 1715826.76% (up 171583527.0% YoY), while the FY2025 annual figure was 89450946.64%, up 110960905336.0% from the prior year.
- FCF Margin retreated to 105.95% in Q1 2026 per MOLN's latest filing, from 114276.0% in the prior quarter.
- Across five years, FCF Margin topped out at 1206596.5% in Q4 2024 and bottomed at 2091687491.94% in Q2 2024.
- Historically, FCF Margin has averaged 122890271.0% across 5 years, with a median of 0.0% in 2023.
- Annual changes were most pronounced in 2024 — FCF Margin slumped 2000000000 bps — and 2025, when it surged 2000000000 bps.
- Molecular Partners Ag's FCF Margin stood at 78.27% in 2022, then tumbled by 1182 bps to 846.66% in 2023, then surged by 142612 bps to 1206596.5% in 2024, then slumped by 91 bps to 114276.0% in 2025, then tumbled by 100 bps to 105.95% in 2026.
- Business Quant data shows MOLN's FCF Margin at 105.95% in Q1 2026, 114276.0% in Q4 2025, and 245715.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 70.82% |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -105.95% |
| Dec 31, 2025 | 114,276.00% |
| Sep 30, 2025 | 245,715.81% |
| Jun 30, 2025 | -171,042.14% |
| Mar 31, 2025 | -103.04% |
| Dec 31, 2024 | 1,206,596.50% |
| Sep 30, 2024 | 4.76% |
| Jun 30, 2024 | -2,091,687,491.94% |
| Mar 31, 2024 | -618.22% |
| Dec 31, 2023 | -846.66% |
| Sep 30, 2023 | 1,164,787.88% |
| Jun 30, 2023 | -7,138.20% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 78.27% |
| Sep 30, 2022 | -6.40% |
| Jun 30, 2022 | 1,286.35% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 1.16% |
| Sep 30, 2021 | 1,476,056.04% |
| Jun 30, 2021 | 5.34% |